Business Description
Active Biotech AB
ISIN : SE0029278555
Total Employee Number:
5Description
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 30.72 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 30.3 | |||||
3-Year EPS without NRI Growth Rate | 27.9 | |||||
3-Year FCF Growth Rate | 31.8 | |||||
3-Year Book Growth Rate | -20.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 2.35 | |||||
9-Day RSI | 22.95 | |||||
14-Day RSI | 38.14 | |||||
3-1 Month Momentum % | 60 | |||||
6-1 Month Momentum % | 220 | |||||
12-1 Month Momentum % | -57.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.14 | |||||
Quick Ratio | 5.14 | |||||
Cash Ratio | 4.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -47.4 | |||||
Shareholder Yield % | 3.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -124.36 | |||||
ROA % | -86.18 | |||||
ROIC % | -255.44 | |||||
3-Year ROIIC % | -639.16 | |||||
ROC (Joel Greenblatt) % | -1532.8 | |||||
ROCE % | -123.12 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.18 | |||||
Price-to-Tangible-Book | 3.13 | |||||
EV-to-EBIT | -2.48 | |||||
EV-to-EBITDA | -2.48 | |||||
EV-to-FCF | -2.78 | |||||
| Price-to-Net-Current-Asset-Value | 3.33 | |||||
| Price-to-Net-Cash | 3.57 | |||||
Earnings Yield (Greenblatt) % | -40.32 | |||||
FCF Yield % | -20.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Active Biotech AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.164 | ||
| Beta | 5.5282 | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 6.64 | ||
| Volatility % | 448.22 | ||
| 14-Day RSI | 38.14 | ||
| 14-Day ATR (€) | 0.024029 | ||
| 20-Day SMA (€) | 0.5385 | ||
| 12-1 Month Momentum % | -57.33 | ||
| 52-Week Range (€) | 0.01 - 3.16 | ||
| Shares Outstanding (Mil) | 26.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Active Biotech AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Active Biotech AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 55 days | ||
| 0.01:1 Stock Split | 2026-06-03 | 0.54 (+1.89%) | ||
| General meeting for 2026 | 2026-05-20 17:00 | 0.64 (-7.25%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 0.54 (-6.90%) | ||
| Annual report for 2025 | 2026-04-01 | 0.47 (+17.50%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 | 0.34 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 0.33 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 1.24 (+0.00%) | ||
| General meeting for 2025 | 2025-05-28 17:00 | 1.44 (-26.90%) |
Show
Entries
Active Biotech AB Frequently Asked Questions
What is Active Biotech AB(STU:BTP)'s stock price today?
The current price of STU:BTP is €0.50. The 52 week high of STU:BTP is €3.16 and 52 week low is €0.01.
When is next earnings date of Active Biotech AB(STU:BTP)?
The next earnings date of Active Biotech AB(STU:BTP) is 2026-08-20.
Does Active Biotech AB(STU:BTP) pay dividends? If so, how much?
Active Biotech AB(STU:BTP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Active Biotech AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers